Ankit Mahadevia
2018
In 2018, Ankit Mahadevia earned a total compensation of $721.3K as Chief Executive Officer at Spero Therapeutics, a 77% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $255,750 |
|---|---|
| Salary | $465,000 |
| Other | $574 |
| Total | $721,324 |
Mahadevia received $465K in salary, accounting for 64% of the total pay in 2018.
Mahadevia also received $255.8K in non-equity incentive plan and $574 in other compensation.
Rankings
In 2018, Ankit Mahadevia's compensation ranked 10,592nd out of 14,244 executives tracked by ExecPay. In other words, Mahadevia earned more than 25.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,592 out of 14,244 | 26th |
Division Manufacturing | 4,266 out of 5,762 | 26th |
Major group Chemicals And Allied Products | 1,609 out of 2,125 | 24th |
Industry group Drugs | 1,358 out of 1,814 | 25th |
Industry Pharmaceutical Preparations | 1,046 out of 1,388 | 25th |
Source: SEC filing on April 26, 2019.
Mahadevia's colleagues
We found three more compensation records of executives who worked with Ankit Mahadevia at Spero Therapeutics in 2018.
News
Spero Therapeutics CEO Ankit Mahadevia's 2022 pay slips 13% to $4.2M
September 1, 2023
Spero Therapeutics CEO Ankit Mahadevia's 2021 pay jumps 130% to $4.9M
August 5, 2022
Spero Therapeutics CEO Ankit Mahadevia's 2019 pay jumps 148% to $1.8M
September 30, 2020
Spero Therapeutics Chief Medical Officer David Melnick receives $1.6M in 2018
April 26, 2019